PKI - Earnings call transcript Q3 2017

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Q3 2017 PerkinElmer Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time.

As a reminder, this call maybe recorded. I would now like to introduce your host for today's conference, Tommy Thomas, Vice President of Investor Relations. begin. may you Sir,

Tommy Thomas

and Good earnings welcome on conference Friel, Executive are Heather. and Vice third Financial Chief the the quarter Rob Officer. Officer; Chief and XXXX call. Chairman Wilson, afternoon you, Senior to President and PerkinElmer call Andy Thank With me

and press note being Investors have our section not earnings website copy be that get is may will at of a you you our live one November Please this on of webcast call XXXX. If XX, our www.perkinelmer.com. website received release, archived from the until

today. our as everyone We change, Before have our if any the any our of views we statements disclaim future update statements today's not begin, on obligation date press afternoon, we need estimates our our in the those in Harbor to forward-looking rely release we view forward-looking as remind forward-looking SEC only that also, of today earlier representing of Any any statements this after of even and made today. statements represent earnings so should issued Safe you outlined to in filings. as

use now GAAP Chief Rob extent financial during that Rob? pleased measures we to the During and non-GAAP the the financial of as available to our non-GAAP attachment, reconciliations this introduce Chairman press of the referring measures to to earnings non-GAAP Executive most in to release. this we'll PerkinElmer, promptly. during not to certain To financial GAAP we we reconciliation A call, reconciled Friel. measure is call measures. this will call plan Officer provide are I'm the use comparable be directly an attachment

Robert F. Friel

at our financial strategic third to previous for progress financial afternoon pleased the on future and on range, results, review high today. quarters, our in will our during communicated relative and continue our of Andy I guidance discuss EPS overall delivered guidance while will thank progress make Similar conditions our more and quarter our the Tommy. update you performance us priorities, briefly previously and market in to quarter revenue very joining detail. our and priorities. to we results excellent discuss PerkinElmer Good end Thanks, you strategic third I'm as with the

$X.XX, to both favorably be bottom And for and low tracking based increasing beginning adjusted original top by on by January are fourth guidance to track revenue during Markets quarter XX% Turning and basis we financial third over results, Year over last adjusted growth Adjusted of $XXX QX year which to generated was our communicated continue the revenue XX on we share per million of of to full-year lines, back points our represents and year. growth guidance double-digits. the date, earnings the in organically. basis XX.X% of results margins of earnings representing X% QX delivering last organic guidance, in are expanded reported our our on year. operating a growth quarter, share our financial exceed X% per and to favorable. growth to the X%

first over in market organic every we we the years, the in For growth which quarter, during operate. region and end the time five third in world of experienced every positive

radionucleotide grew markets, emerging digits from offset mid-single and strength mid-single headwinds grew as was Diagnostics our specifically to Looking continuing continue markets. developed outpace at end biotech business. high service imaging markets pharma our content digits in also as in

Asia, strong in declining in from and continuing strong, to strong new over positive performance Our revenue by as due recently key environmental Americas, food markets results industrial XX% is low several business in customer growth was single-digits very and products. wins Europe. Both see growing introduced grew to offset environmental

to low funding the single-digits to improved. are sales outside customers U.S. slow the also grew start year academic recovered as a – Our and has from

now core spec our very we new our Diagnostics, strengthening and have while continue our positive received make to the for addressable customers. initiatives, response expanding a good performance platform, our QSight, market progress within our strategic we areas, mass launched Turning clinical to markets. our against In QX, from

During registered a the the Class with FDA. X third instrument quarter, was QSight as

our have continues encouraging offerings both for throughout Tulip Indian are the in lines Tulip's and for HIV business In diagnosis malaria, greater in address completed diligently newborn access solutions addition, of our the to existing prevention, which we to emerging such as QSight. escalating across India. the the quality and applications CE that screening and bottom and be new enabling hepatitis, assays European issues market, as our top diagnostics we and the on on expand communicable are to add working of These we in critical beyond performance clinical world. the The extend used Diagnostics diagnostics diseases is marking regions. in-vitro Moreover, portfolio demand to healthcare instrument clinical screening, part in

cord our and market hopefully research Phase The cord shows and the to potential this helping by blood to the of drive briefly cord the this treat over cerebral developments and own seen greater newly you banking encouraging to Turning ViaCord some clinical Duke related of led tissue our blood time. may cord use palsy. tissue participation business, of published families, child's II have year University, trial earlier of that awareness with by penetrate from blood announcement further cord will around a

key initiatives to on that continued quick also thought good make would and business progress discussed previously our growth a I've the Diagnostics provide I for We update.

month, we precision on with that NGS enabling much will alternatives. to These validate expensive to option solution and platform, year-end. testing shortly. expect less date, and before efficient the to article our the and before, Europe last more To we As a before article will versus has NIPT for results I've commercial look very demonstrating should current NGS-based current One we assay. compares be year-end, In more alternatives. automated the screening research as which mentioned installed units another high to Vanadis well continue its data in an prenatal submitted be submitted be an performance, system platform published very imaging encouraging in leverages have Vanadis is another and the continue generate installed been the data

a As and the potential continue for about to our enthusiastic very confident result, first launch year next Vanadis be the half that remain be we for met. commercial date will

with offering already rare institutions of PerkinElmer have sequencing testing Genetics disease academic of begun and pharma both samples we companies. Our whole a services has genome signed contracts number and

wide announced conditions. Genetics brings across which During the of also PerkinElmer our third collaboration supporting quarter, genetic range IDG's neurological In-Depth is program to or patients a IDG. we Genomics with diagnosis

R&D, clinical and then a and of reporting genomic genome use services interpretation whole to provide of to will sequencing, data de-identified cause We the IDG hundreds understanding support rare their the diagnostic clinical better diseases. of IDG generating and will

capabilities business allergy as closing We our of focus EUROIMMUN, with reproductive continue year And remainder of is to our of these acquisition rare our around be the our our testing. health opportunities we of finally, for the offerings autoimmune the and immunodiagnostic pipeline diseases. one augment of and excited which about major priorities will

future has great between to It The few used been and this collaborative closing progress past also planning QX approval we hurdle employees Over we to in discussions one are we've this explore forward only the period facilitate opportunities. a time working is remaining have and towards both closing. for months, made of and China we exciting very looking are still much to an regulatory organization. uniting as companies

the look will commitment we this for end purchase either currently, is occur, commitment. presented outright to at simply by the until as of our forward shares am after this continues If we as happens. with spending As it more shareholders unlikely I EUROIMMUN's encouraged ever soon extend and combination. or employees to timing opportunities time the determine minority shareholder of the this I the year. And closing communicating by leaders those EUROIMMUN,

the interest of among development and food, science customers over year across created the ago, Several opportunity, to are and business, significant continuing growth date, DAS industrial Year we launch number XX of instruments undertaken slated which by market detection improve in couple our the research attractive investing imaging we've to of in have was the still are generating achieve new to to to launched commercial actions environmental, most more which profitable months. while a execution. Moving and accelerating significant one objective disproportionately next markets. about life

capabilities, specifically testing developing at seeking to and expand Looking food our innovations portfolio. our also while quality we franchise, which safety continue focused $XXX food on is assets attractive adulteration, to million-plus new acquire

to just and high sugar Europe These a measurement we number the Australia, During unique a food demand Perkin content, grain few. applications reflect large textile of for Delta based of technologies. product the won utilizing quality China U.S., the establishment fermentation quarter, the grading analysis, include that tenders of whole production, and spanning on and a for cite

manufacturing on an standpoint, our range in are competitive pharma is quarter, as our of end On solutions implementation the third service market of has lab the contract ability and provide we in services the our the during technology-based we execution focused a our largest improve lean which third the offering A component Also, the and and scientific margin asset to strong to continually progress customers to on history making due recent profile. business our lab higher space the faith into offerings customers' in XX% services their OneSource expand significant key experience continues initiated manufacturing insights In our XXXX. margin operations, facilitate our represents was improving utilization by the of particular, well the as resulted in the initial win, win evidenced which which execution of operational management has strategy, From of our location. with from to to globally good additional the of strengthening a OneSource. side, methods reduction have new of since indication in breadth our floor tenders our offerings. operational

from recently of addition, timeframe, our important footprint opening confident an reduced to of of revenue these of In we improve our points several by total next years. of the produce research as enabling remain and the revenue, have manufacturing of solutions additional significantly increased us during future to with of last percentage in increased XX world. DAS and leverage in facility to ability in facilitate XXXX families. for in products same higher basis our us into XXX several our location XX% new or to I accelerate our our and better make a to revenue broaden over beyond. to expansion Also, investments should aligning product our been development of XX% Chinese innovations percentage as have customers, believe manufacturing a initiatives By the others, have as translate material Through growth the basis year, and well Relative capabilities serve to will XXXX, product in points markets. sales. attended gross we costs, ability These costs enable cost important R&D the SG&A area we as this operation margins growth improvements, in our which investments to of R&D

exceed So to to continue financial summarize, during quarter, meet our the we commitments. or

of market our successful Andy. the afforded over the by I'll in upcoming both like accelerate execution the the to and belief However, combination the line and now call turn XXXX importantly, acquisition, our of bottom to opportunities our initiatives, conditions beyond. growth reinforces of more top EUROIMMUN and should favorable strategic that growth the

Frank Anders Wilson

guidance our continued well as fourth pleased of Thanks, around Rob, grew provide summary months Consistent color quarter quarter, third end continuing million. performance XXXX, $XXX with as X% of the We quarters, revenues operations the as on details the everyone. our additional with our first from financial markets, I'll third and a previous adjusted nine in to for and afternoon, good were quarter. some

of quarter growth introductions Asia, growth digit new macro major improving healthy by revenue single-digit experienced grew of both XXX organically product driven representing the approximately all sales, growth our basis, quarter in in a by growth low the third year-to-date diagnostic exchange high driven and in Foreign organic BRIC additional across Discovery approximately genomic moment. and total with Europe. continue color on Analytical tailwind basis to third total organically revenue growth revenue on organic strong and and solutions. in in grew based revenue in the In both single-digit double-digit market with environment. I'll in provide sales, our broad and growth of an adding representing X% points basis By and organic we an year-to-date, approximately mid-single X%. XX% X% China. XX% expect in & with growth geographies businesses of sales regions, revenue advanced emerging business, in the offerings a XXX organic organic represented some acquisitions resulting of points, organic growth continued Diagnostics, a We Americas, X% Solutions,

to operating partially expanded points driven to investment quarter XX margins XX in R&D expanded have operating year-to-date. by SG&A margins by year-to-date. As points the results, third basis operating quarter Adjusted increased over adjusted leverage, XX.X%, offset our continued and basis

for I end a share to $X.XX, at As about more will Year our adjusted adjusted continuing increase of our our R&D from quarter of prior versus in spite a year XX% the result, increase earnings was earnings XX% third the approximately high talk operations of date, per and per XXXX in the investments, which range. guidance has a XX% increased shortly. share

the advanced were let's in line to Varian the offerings, which the in segments with and into business drivers further emerging by in diagnostic prep quarter driven our Looking sample results with third quarter, for Americas business expectations, market key third within our continued our outperform. our genomics, start Diagnostics, strength

Our another the gain while to exceed growth as continues customers' clinical strong market, serving traction Tulip expectations. quarter business, needs, had continue they to addressing Indian labs out

investment mentioned continues Smart we for basis which Within tool set Health Public As recent a both earlier, spending, investments spec We're the screening. driven Diagnostics, Vanadis' to newborn for Conference businesses. is spending our pleased in for on report well year-to-date quarter a ramp be and and at screening continue that received newborn by increased focused to has NIPT mass launch. to on new this fourth Association Labs R&D was

were, focus services, once industrial solution, in submitted and environmental academic again, Vanadis, publication. with internal biotech driven single-digits. our expected Analytical grew often areas track government and Switching results continues growth as Solutions business, our our as for as to plans strength by a while very pharma to strong recently revenues While Rob played we key in & NIPT data low food quarter of third well Discovery and offerings, and from out mentioned, innovative as to

and results by were Looking while again at new food the growth biotech OneSource food growth by environmental by for performance. and very key products, strong ICP-MS a Perten continues be in to overall driven driven was pharma once solid applications, driven

recent customers, sustainable significant growth, very continues drive now into the growth that are to double-digit will OneSource customer team OneSource our wins existing coupled of intermediate term. an year-to-date. experienced services of the quarters a pleased believe expansion near with We We new with be for industry-leading number in has to

inorganic have In with terms of a increased new developing product and number been of ICP-MS R&D lines. spend and within applications focused have secured recent on DAS, targeting products, we wins launches in ICP-OES

new gas We orders in that acceleration taking are to imaging organic drive an launched excited also XXXX. help on our chromatograph, be growth instrument newly should

year-to-date January was interest the tax with line third expense is be rate full-year line, XX.X%. the approximately below Looking $XX guidance. below approximately approximately slightly net and the in XX%, rate we And other tracking expect for quarter initial our tax our adjusted to while our adjusted million, guidance,

billion of X.X debt-to-adjusted-EBITDA with we and the entered balance of $X.X net times. quarter approximately we to with debt ratio million quarter of cash, Turning and approximately a sheet, the the finished $XXX

As to EUROIMMUN. of debt cash we expect and use have acquisition to incremental mentioned, fund we a combination of the previously

details We will communicate upon closing. these

for approximately Turning cash $XXX and will efficiently million. to balance ahead believe working flow, operations XXXX, was adjusted continuing manage requirements cash that flow from as we drive we flow the to we cash capital to And year-to-date of $XXX our the free operating continue of look million year.

deliver Looking to solid of believe year. we the are quarter finish to well-positioned fourth the we XXXX, to a

expected be the range to organic $X.XX per to to represents approximately to growth For to quarter, million range share the reported we are the X% and revenues forecasting million, of of of in adjusted revenue $X.XX. $XXX be earnings X%, fourth are $XXX in which

of represents the time, growth As to we'd organic Rob of prepared the share concludes questions. EPS of midpoint XX% for the at mentioned, and for this like approximately $X.XX. updated $X.XX of up growth at this revenue range Heather, earnings per to my adjusted open X% year This remarks. call full-year the

Operator

you. Thank

William with question comes from first Janney. Your March

open. is line Your

William March

Hey, guys. How you? are

Robert F. Friel

Good.

William March

launched, you are sequencing cross-selling portfolio? core who versus bit just margin this existing diagnostic diagnostic target whole you there a the could business business product? Are specifically, maybe customers the just opportunities question, your genome about And maybe that with First of the just some little talk profile this then, business? the for

Robert F. Friel

sure. Yeah,

at So, three it's targeted customers.

all, I area, of in First area that think health and of our reproductive is a lot there opportunity. cross-selling

confirmatory So, often I think talked testing. quarter, screening we about as newborn into NGS our for last very reflexed is business

of So, we're doing confirmatory one now is some testing of our the with doing things newborn we're customers. screening the

some is have are of where The like often reproductive course, whole other good see those that interest done. business, our stored, cords very some the we where have synergies see we where in area sequencing genome with ongoing business to would XXX,XXX where area ViaCord health and we customers

that's area I say we're focused the first So, on. that would

area was mention orphan that the companies with then pharmaceutical would IDG having work the mentioned do with for them remarks area I the disorders. pharmaceutical where identify to And sequencing prepared I second help patients doing The several be in and genome neurological to one with particularly particularly working potential the us in the clinical regard whole some would they're studies. where we're in third area, we're drug,

we get even So, volume that And days a early do maybe a as business. better but the to We're average. company update. the get of equal anticipate bit than I seeing little while operating margins focus that's we good we startup would the initial the the it's right say can now, higher or

William March

was kind on bit a or geographically each about three that if quarter, you on what just a what quarter this the just saw seeing comp Thanks, we of more a commentary double-digits seeing low maybe geographies? guys. of tough I in that know you're whether then, if Asia, And it. you're – comp of Got had terms talk could in more you last little difficult

Robert F. Friel

I actually is before, the EMEA as the first one So Americas, or we in regions, quarters whether three so where experienced growth while mentioned of it's this all in a APAC.

And so, of see those, I of pretty we than that, across in see the little maybe good if other at But look with a Diagnostics. the all exception good growth continue U.S., academia to generally I each think we growth was areas light.

down you we say look bit, you if quarter, now a I of flat. would more of on the I more ability while of expand now the this first pharma basis, third sort side, Diagnostics it's have end newborn, well a the what continues actually do, the saw all, we mentioned trailing say on the U.S., look to flat in would births At if seeing growth them XX-month quarter, little to So, environmental the good prior think, now. continue sort do areas. we to and our expand testing safety of that But menu we're to business also and genetic at and

think I demand good the So, Americas. within

Europe, of led us exception again, obviously, pharma for at And strong China. the was think the in in a I probably Europe the mid-teens you and China area very pickup say that industrial, U.S. was of strong growth the was not I then, more the by food aside, across highest for sort as us, on possibly markets APAC, was but industrial with that when good was and issue. look strong. pretty comp course, up of on really board would strength a saw as we of and

business look industrial year, last our I high-teens. at up you if think was China,

pretty remarks, prepared So application all good areas. strength, the across again, and sort in seeing across mentioned we're globe of as I the my

Operator

you. Thank

Your Dan with next question comes Citi. Arias from

open. is line Your

Daniel Arias

commercialization Germany, should Europe? can a think in broadly get about on that next we be or fairly it seeing you Hi, Vanadis, quickly? talk be to there, about thinking Thanks. going Rob, France, Is just how guys of UK, availability you all you're meter kind guys. rollout year for ready as will

Robert F. Friel

Yeah.

first. I Europe think, you mentioned, as that will be

these to XXXX things I some time as for to countries. we think at the best we're some metered and of want the relative we somewhat it and be by as of tenders. try the will to at can least tenders that in the revenue one That's of potential in looking

markets, large I up gets at the ramped initially, you be market. XXXX, if Again, a the of of already, aspects broad commercial determinant screening. But is into goes important more one leader we've biochemical So it the basically, to the would Europe. across look this intention because quickly the strong talked footprint that'll this based about, we've how think again, biochemical got be in pretty of markets very in as in a in, those

quickly. So, we something this be think will we penetrate relatively can

will CE just really remind, else. gated actually, the it more to by plan the to of, marked, Western So, so markets more us our tenders, it is anything access Again, give than than again, will Europe. have just be timing other the

Daniel Arias

the about And a terms during to And what helpful. U.S. then, touched with EUROIMMUN sort really the quarter? of but this a chance are that you've That's apology you organically to on in that about in how remarks you if had Okay. of meaningful think associated that way? now did prepared business, thinking timeline bringing portfolio do during the

Robert F. Friel

So, to well. EUROIMMUN do continues

they if continue through three I in quarters, growing the you of results we assumed in the organically what high-teens in say area. the XXXX So they're model. excess in grow at to would look

And market to several penetrate sort we of the been so, can prepared how be spending the as over on fair possible. the amount of a U.S. weeks as last one have is we things time quickly of

that will in that top clearly the collaboration discussion. be we've priorities one the so, identified and synergy And of

try So, the drive in relatively be really and would plan growth to quickly. the U.S.

Operator

you. Thank

of comes Lynch. Merrill America question de Bank Derik next from Bruin with Your

is line Your open.

Derik de Bruin

afternoon. Hey, good

Robert F. Friel

Good afternoon.

Derik de Bruin

that Hey, with I just own you on curious, spec historically anything that could remind system? on you area change mass you and does partnered for about of sort of your launch as believe screen that the I'm the us aspect, relationship, relationship I have just guess, in newborn market. that Waters

Robert F. Friel

Yeah.

of spec we the the in from and software and the all far, our also filter else detection was information that sample as the in customers, solution, informatics. used go to the service So, right. information historically to our then, Waters mean, paper relationship The and fundamentally, the I puncher solution. when you're was preparation that the again, to everything we mass we

QSight, be moving the So Waters plan now forward replace mass the with the would to QSight. the with spec

will And be exclusively forward, solution. so, it PerkinElmer an going XXX%

Derik de Bruin

Great. biochemical-based, are sort in is it's the mass questions immunoassay the market? market These penetration of staying that spec market the that guess, how typical a like And I spec-based and mass screen-based opportunity. like that on as just of follow-up, much versus what's for

Robert F. Friel

Are you talking China? I'm about sorry... or globally

Derik de Bruin

I'm on talking mass is basis a in globally, spec of on being about where global used... terms

Robert F. Friel

if So, developed would outside large mass piece spec is course, markets, look of of the small But I relatively say a today, you from markets a are perspective. penetration developed it. the

opportunity perspective, the of more from expand is say is probably So market, most the don't look the again, market, spec, probably mass the would covered XX% an biochemical. roughly the you just markets XX% going do and biochemical. current I to They opportunities mass of spec today. market at today forward emerging When and by do

Operator

Thank you.

Your question Patrick comes with Donnelly from Sachs. Goldman next

open. is line Your

Charles Steinman

for Charlie Patrick. for Yeah. taking Hey, the questions. is on Steinman Thanks This guys.

penetration OneSource, to the who product of also increased on regarding hoping OneSource, you've customers any seen on if from get potential Just hadn't then, side was of pull-through sense a an And relationships? those before? outsourced

Robert F. Friel

the particularly outside we on the yes, one, to customers incremental So penetration U.S. of continue see first

a early sort forward. think question the on that's And of it's good there. significant days And growth so, the of component I second going is

significant more for a that's think I us going forward. opportunity

on PerkinElmer sort the hopeful, later, more and products. we're we get as of get be that XXXX able pull-through So, into we'll to

Charles Steinman

the little that's DAS side you've curious one on And two the and years? ramps but a nice of Diagnostics question, Thanks. next just I'm or focus. acceleration maybe high had Great. a level more on that clearly, growth a then, a the of over side, up been the what, Okay. business

Robert F. Friel

as and on nine combination out imaging or of new we've XX the products, so products detection of marketplace, we've So, I mentioned in (XX:XX). over the get I things. new I so, marketplace And months got one. the some think we've focused out That's think all, products last it's got been first to into and new

areas be we've and out positions. applications both ones the food, investing where ICP-MS. got the those our competitive think spike is The specifically think capabilities, greater of finally, area, other services thing opportunities and in maybe, in I inorganic I imaging growth I would And and some pharma disproportionately ICP like would stronger the

sure area just of those making So, our the areas. expanding in then, focusing is And really we're sort other capabilities.

I in And products think DAS closer else needs that regions. line just also, to recently be our nimble starting we of China capabilities of quickly, to more So, where our I to mentioned very specific of adopt our those opened locating geographic up to fact the our the and for more customers a more manufacturing and products. respond more

areas think are sort those think that I growth the So, drive three I for key can we of DAS. organic higher

Operator

Thank you.

Your Tycho comes from with Peterson JPMorgan. question next

Your line is open.

Tycho W. Peterson

could the and coming X% through you seeing things. just fourth much us modestly Hey, of of where improvement hitting came if in in just Can Maybe thanks. implies Rob, quarter? comp A the gives what And trends you quarter quarter. the fourth out against you're a shortfall couple of the doing tell logistics tougher this organic how the you quarter bar? quantify that? in then, guidance confidence your

Robert F. Friel

Yeah.

the like that QX. revenue So, of missed in XX% if we we I felt all, got not, think we

mentioned latter think quarter I early of we we the the actually shipped think and last felt all majority shortfall the is spilled part I I instrument because maybe into was it that. August, side, of by had on the July

achieving sort to think the So, relative that top our to this our was end quarter. guidance of I helpful of

and that's on think traction starts products, food. the with I it seeing, to think new we're so, the areas driving off relative I getting the

think as I in fourth things start or And up. that quarter nice mentioned OneSource, we one the side. to so help a some couple win here ramp place I think in at we in least the I Diagnostics us of got program the that think on we've that'll

at on to genetic think some some in the side, we've starting see expectations quarter. improvements, growth QSight, fourth nice see the we'll I where some testing it got

alignment we targets for that we've pretty good out got to So, QX. think the growth we've laid

Tycho W. Peterson

or see Is low-single PMI on (XX:XX)? upside And for growth little what to a front guess, we industrial, improvement seems relative the bit there side. on in industrial light I digit the room

Robert F. Friel

Yeah.

mentioned QX tough relative I comp was think last we China up in before is. that there pretty a year, to it had I high-teens.

a was that bit we seeing I the I markets issue. comp So, implies your that. think we're question think would that with little industrial and agree But a of end recovery some in

think we but see pick didn't XXXX. QX industrial as to So, be up into start would in we if here, we only I not get disappointed

Operator

Thank you.

Your comes from next Stanley. with Steve Beuchaw Morgan question

Your open. line is

Steve C. Beuchaw

and questions. taking thanks afternoon good Hi, for the

could sense leave us a if, we I year-on-year is inorganic, for one out currency other, M&A to for get can I else at the or to wonder anything you from organic Andy. First here. year-on-year Andy, the so give impact margin. if want an from line, you don't and margin

Frank Anders Wilson

Yeah.

think maybe cut by expecting at I EPS But level. an at from don't and EPS start time, $X.XX I'll quite be we with really tailwind. operating an perspective, point this year I we margin an in the that into – went and it FX to expect have because FX then headwind,

So, our we the $X.XX, higher provided. if at about guidance than you of a look $X.XX guidance, it's with January midpoint

thus that benefit. R&D And spent is have we in which resulted far. then, about on but a we the back operational So quite with beat obviously, that, covered a bit $X.XX,

is of at The in fall year the Delta The amount side, example, just, fourth would So for over both think I on point. the think about for and be will continue in revenue quarter. us little M&A year-to-date will it's FX that all the that I and all, for $X.XX. half in a $XX and $X.XX off acquisitions the million, Bioo the second

Steve C. Beuchaw

that all of... inclusive sorry, And is

Frank Anders Wilson

the That the beginning was all in at of year, our guidance yes.

Steve C. Beuchaw

contribution And second wonder recently dollar the relatively new of some launched thinking these if new this the that the those is about those products. from on I you your flow product could then, how driving XXXX? have that products remarks Q&A here contributions the half, of numbers And Great. on over through. new those outset at past the great of the years, been and commentary a lot this coming of call, a of talked see and times year prepared then, year, In products lot considering for and here I Thanks. product at to Okay. there's about put the though, you've the mean, year. during the in course about

Robert F. Friel

And important of of great has Steve, focus ours and take because been a an initiative I'll ours. that. that's a it question

new products, year about of track you a new quarter, if from you $XX through And the and help first year was it in million So million in said, the products, think the look at it we if of we started of sort looking the off sort at we're range. incremental. sort $XX

million. above $XX For the think the like for $XX quarter, third more a million was about is We that, third the maybe second just tad maybe quarter. quarter it

million. now actually, nine our months, we're $XX a So bit the above of target through little

good lifeblood that drive point, innovation your And progress growth. to and ultimately, we're markets sure of is we're the in attractive the our is key about making think to the I that, make bringing customers here. incremental we're our end we So The feel to to growth.

very And pleased so, we continue to be with that.

this traction just confidence team. As we new all, as the we into of in, we'll give in next of our to get how of of And year optimistic. as we because guidance and the mean, importantly, products, about XXXX, sort it think part earlier be process we're I the year, driving continue but XXXX first reinforces obviously,

other upgrading to the and of it's over organization difference. have it's a is the aspect that see the leadership last great been making So, R&D we months, XX maybe the

Operator

you. Thank

Your Leonard next Deutsche Bank. with comes Dan question from

line Your is open.

Dan Leonard

you. Thank

an to Are leverage standpoint. revenue going to that and questions. you percentage bit two year of continue thinking a beyond So, line you reset you're on of up that seems you R&D or will XXXX? from aggressively invest a How leverage about as go continue get XXXX think do going be forward? to to would a

Robert F. Friel

when out for back, something X.X% I mean, at R&D And of year-to-date, spend. X.X% targeted we sort operating I years couple of we're or XX% like set I margin we think targets X%, the the No. think that.

of area. So, we're relative to product in you then, comfortable the up number. I pretty think with it that when it almost gets X% about revenue, X.X%, you think And sort

So, I think we're now. fine there

with into spend percentage R&D. more course, coming they as Of EUROIMMUN the do of company, a

But PerkinElmer the and that fact, ability percentage in but sort with drive growth are call in the where coming go think areas seems relative our the we portfolio, for up, see, that I math a to will now we've good important organic the the, are we it you I'll historical EUROIMMUN of about. just I I that's R&D So in. talked pretty think think exercise to invest think

Frank Anders Wilson

expand think some really, it's and and And our investments room we get little to XXXX. well And that R&D margin the on it still then, to XX% leverage a that combination as have investment, discussed, growth kind bit, we map we to of by efforts it's framework expansion as have also some R&D of of accelerated a really gross the SG&A. to just of from a road the Rob organic it's a but

think I to were in our longer think line, we're Rob and I as achieve goal. term and still make said, right So, those we investments able

Dan Leonard

question. And then, Okay. one follow-up just

XXXX? the products, pluses good line you're minuses I'm but screening good to is on that into X points. organic and the top about in XXXX and maybe in there? guy offsets? Is that's offer the year-to-date bad all a you coming What So, is better something a guide, can RAS, and and sounds in are new color it newborn growth a turn on What like understand it besides can trying year-to-date guy

Robert F. Friel

I No. do the X% we've sort guys is beginning on track right Diagnostics we that Diagnostics of or year. in the generally, to talked I think feel in bad of about there's like the X% now. any mean, don't organic

new offsets the of think I haven't where within invested we DAS. are the the areas sort products in in

the fair ICP, amount about AA. organic a thought we portfolios, ICP-MS, so even So,

and areas in in material be we'll the areas hopefully like of the of areas more think XXXX, around I thermal able chromatography focus to characterization. that some some the areas, on the

some the probably again, not there investments growing support food areas of we're those the So, may that we're areas market because, some I we making et with think focus or – where in other or pharma, not of our some the support are area cetera.

Operator

you. Thank

Emily with Robert Baird. next W. from Your comes Stent question

line is open. Your

Emily G. Stent

for Hey, my questions. Thanks guys. taking

can recurring you from capital looking revenue? at how versus out market, saw much off, the pharma you growth First break equipment end

Robert F. Friel

a that we imaging the discovery. by flat, include basis, offset growth. like product radiometric services, if and in recurring at sort high products would you doing of we content were when detection I imaging of I couple look would on things say say relatively other and would well being of be basically a the drug majority

the was growth. flat. So, relatively product was majority Services of the

Emily G. Stent

makes That been an update? next to August, CFO sense. going to search set replacement with and retire And when Okay. Andy how's then, the should expect hear we

Robert F. Friel

start hired I it's some a it's to qualified We've very to seen search early I'll well. candidates. days. of off impossible going list But having preliminary be Well, replace it's Andy. saying said We've firm. mean, that, by going

I pretty so, person to And about good think we the strong get feel in ability a here. very

into middle a give time, I nice willingness of shape thing as should fair in good I be think Andy's of of the think get XXXX. us amount is because we of sort to part we

Operator

Thank you.

next Jack Meehan with from Barclays. comes Your question

line Your is open.

Jack Meehan

Hi, thanks. Good afternoon.

Robert F. Friel

Good afternoon.

Jack Meehan

focus end So, the on growth the food wanted in market. to

So, prepared in I think I XX% the caught remarks.

think I teens the we're expected be than better trends was a for. on to elaborate into there. but you're little the it feel Maybe seeing that swing looking just

Robert F. Friel

Yeah.

of just then, leveraging saw see combination PerkinElmer bought – there, trying and we're the it expected. in which we able Delta, we been there. the process a to I to think also, channel, growth. And bought of larger probably once Perten, in food to I do we're continue Europe in of quarter, takes that the And we customers some So to and very channels additional it's getting strong is we're strength we're think leverage think particularly of in we've and some and products. some We bought Bioo, we continue historical of integrated, a China, traction time into we and strong nice sort those I of some growth get to see this starting

versa. through or products or PerkinElmer either So, pulling vice Perten Delta and

Jack Meehan

be can into quarter double-digit fourth may the Do you growth and XXXX? into think sustain

Robert F. Friel

target I single. high in food we would sort of say

in think But would low say food see sort the quarters, teens. is guidance our something the I built we QX of probably into I could given in double-digit in range.

Operator

turn Thank like closing over to remarks. showing no I'm further the Rob Mr. this Friel you. back questions for time. to at I'd call And

Robert F. Friel

priorities. of about on Thank financial great your our strategic Well, we And well as progress you appreciate in have year-to-date, performance we all, feel good make for our first we evening. continue to your Great. questions. PerkinElmer again, a interest the and as

Operator

Ladies program wonderful participating gentlemen, disconnect. and in you Everyone, may day. This you does have today's thank and all conclude for the a conference.

Revvity (RVTY) 2 Nov 172017 Q3 Earnings call transcript